<DOC>
	<DOCNO>NCT00085384</DOCNO>
	<brief_summary>RATIONALE : PEG-interferon alfa-2b may interfere growth cancer cell . PURPOSE : This randomized phase I/II trial study side effect best dose PEG-interferon alfa-2b see well work treat patient ovarian epithelial , peritoneal , fallopian tube cancer resistant platinum-based chemotherapy .</brief_summary>
	<brief_title>PEG-Interferon Alfa-2b Treating Patients With Platinum-Resistant Ovarian Epithelial , Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine optimum biologic dose PEG-interferon alfa-2b patient platinum-resistant ovarian epithelial , peritoneal , fallopian tube cancer . - Determine safety tolerability drug patient . OUTLINE : This randomize study . Patients randomize 1 3 different treatment arm . - Arm I : Patients receive PEG-interferon alfa-2b ( PEG IFN-α ) subcutaneously ( SC ) day 1 , 8 , 15 , 22 . - Arm II : Patients receive PEG IFN-α SC ( high dose arm I ) day 1 , 8 , 15 , 22 . - Arm III : Patients receive PEG IFN-α SC ( high dose arm II ) day 1 , 8 , 15 , 22 . In arm , treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patients follow least 28 day study treatment . PROJECTED ACCRUAL : A maximum 75 patient accrue study within 19 month .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Women platinumresistant epithelial ovarian , fallopian tube peritoneal cancer whose tumor test positive IL8 ( &gt; 31.0 pg/ml ) , bFGF &gt; 7.0 pg/ml ) , VEGF ( &gt; 700 pg/ml ) . Resistance define : 1 . Progression disease platinum chemotherapy , 2 . Progression disease within 6 month complete platinum chemotherapy 3 . Failure achieve complete response , persistent macroscopic disease , 6 cycle chemotherapy , last two cycle measurable change disease status 2 . Patients know hypersensitivity platinum compound fail desensitization regimen , good candidate desensitization eligible . 3 . Patients limit 4 prior chemotherapy regimen ( platinum taxane regimen count one ) . 4 . Patients must measurable disease . 5 . Women racial ethnic group . 6 . Zubrod performance status &lt; 2 . 7 . Expected survival &gt; 12 week . 8 . Patients must adequate hepatic , renal , bone marrow function , define serum creatinine &lt; 2 mg/dl ( estimate creatinine clearance 50 ml/min ) ; total bilirubin &lt; 2.0 X upper limit normal ( ULN ) ; alanine aminotransferase ( ALT ) &lt; 2X ULN ; fast triglyceride &lt; 800 mg/dL ; white blood count ( WBC ) &gt; 3,000/mm3 ; absolute neutrophil count ( ANC ) &gt; 1,500/mm3 ; platelet &gt; 100,000/mm3 , hemoglobin &gt; 9 g/dl . 9 . At least three week must elapse completion chemotherapy . 10 . Patient agree use complementary alternative medication ( e.g. , shark cartilage ) . 11 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . The approved consent append protocol . 1 . Patients borderline , low grade low malignant potential tumor eligible . 2 . Patients pregnant lactate . 3 . Concurrent chemotherapy , radiation therapy surgery . 4 . Concurrent , uncontrolled , medical psychiatric disorder . 5 . Patients know hypersensitivity interferon . 6 . Patients severe cardiovascular disease ( i.e . arrhythmias require chronic treatment congestive heart failure ) ( NYHA classification III IV ) . 7 . Patients interferon within last 6 month . 8 . Patients overt psychosis mental disability otherwise incompetent give inform consent . 9 . Patients know autoimmune disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>